Evidence map›Paper›PMID 32380908›Full record

Trial reportStem cells and development2020

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.

Vikram Sengupta, Sascha Sengupta, Angel Lazo, Peter Woods, Anna Nolan, Nicholas Bremer

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells and development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06002841 (Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies), which is not on this map. Cited by 455 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
455citing papers in PubMed, 8 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06002841 phase1 / phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies: a Clinical Trial, Randomized, Double-blind.

TypeinterventionalSponsorD'Or Institute for Research and EducationRan2024 to 2025Enrolled15ConditionsSevere Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), PneumoniaArmsintravenous treatment with EVs, intravenous treatment with placebo solution
3 · Its place in the literature

Who cites it

455 citing papers in PubMed, 8 syntheses or guidelines pooled it, 740 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

395 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vikram SenguptaDepartment of Internal Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Sascha SenguptaThrivewell Infusion, LLC, Brooklyn, New York, USA.
Angel LazoDepartment of Internal Medicine, Englewood Hospital, Englewood, New Jersey, USA.
Peter WoodsDepartment of Internal Medicine, CarePoint Health System-Christ Hospital, Jersey City, New Jersey, USA.
Anna NolanDepartments of Internal Medicine and Environmental Medicine, NYU School of Medicine, New York, New York, USA.
Nicholas BremerDepartment of Anesthesiology, NYC Health + Hospitals/Bellevue, New York, New York, USA.
Englewood Hospital and Medical Center · USNew York University · US

Funding

Metabolomics of World Trade Center-Lung Injury: Biomarker Validation, Longitudinal Assessment and Dietary InterventionU01OH011300 · OH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NOLAN, ANNA · 2017 to 2025
$4.8M
RAGE Mediates LPA Induced Pulmonary InflammationR01HL119326 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NOLAN, ANNA · 2015 to 2019
$2.1M
NHLBI NIH HHS R01 HL119326
6 · The paper itself

Abstract

This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO

Indexed as

Mesenchymal Stem Cell TransplantationAdultAgedAged, 80 and overBetacoronavirusBone Marrow CellsCell-Derived MicroparticlesCohort StudiesCoronavirus InfectionsCOVID-19Critical IllnessExosomesFemaleHumansMaleMesenchymal Stem CellsARDSbone marrowCOVID-19exosomeMSCSARS-CoV-2

Identifiers

PMID32380908
PMCPMC7310206
OpenAlexW3023922995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.